| Time | Session |
|---|
|
10:45
20:00
|
Adquired resistance mechanisms to KRAS G12C inhibitors in lung cancer
P-308
EACR25-0003
Marc Cucurull Salamero
Poster Presenter
Spain
|
Novel Topoisomerase I (Topo1) inhibitors with a non-Camptothecin core scaffold to overcome resistance to current Topo1-targeted drugs and ADCs
P-309
EACR25-0051
Qun Dang
Poster Presenter
China
|
Chemotherapeutic Response and Resistance in a 3D MDA-MB 231Triple-Negative Breast Cancer Spheroid Model
P-310
EACR25-0163
Beynon Abrahams
Poster Presenter
South Africa
|
Overcoming Gemcitabine Resistance in MDA-MB-231 Cells: A Synergistic Approach Using ABT-737 and NVP-BEZ235 Dual Inhibition of PI3K/mTOR
P-311
EACR25-0209
Gizem Selimoglu
Poster Presenter
Turkey
|
Bacterial modulation of 5-FU chemoresistance in head and neck cancer
P-312
EACR25-0229
Lee Mai
Poster Presenter
Australia
|
Investigating AMBRA1’s role as a prognostic biomarker of resistance for melanoma therapies
P-313
EACR25-0247
Christina Tsiavou
Poster Presenter
Sweden
|
Variable responses to Akt kinase inhibition stem from non-genetic heterogeneity
P-315
EACR25-0303
Colin Ratcliffe
Poster Presenter
United Kingdom
|
Acquisition of resistance to targeted therapies in lung cancer: mechanistic basis and suppressive strategies
P-316
EACR25-0351
Jos
Poster Presenter
Portugal
|
BET inhibitor Birabresib synergizes with PARP inhibitor Talazoparib in urothelial cancer cell lines and patient-derived organoids
P-317
EACR25-0379
Jutta Schmitz
Poster Presenter
Germany
|
Activation of the Integrated Stress Response to overcome multidrug resistance in cancer therapy
P-318
EACR25-0505
Jorge Mota-Pino
Poster Presenter
Spain
|
Targeting DUSP6 to combat therapy resistance and brain metastasis in HER2-positive breast cancer
P-319
EACR25-0601
Shruti Nitin Bhardiya
Poster Presenter
Finland
|
Understanding and targeting mechanisms of resistance to the cytidine deaminase biodegrader and gemcitabine combination in cancer
P-320
EACR25-0637
Margot Cristol
Poster Presenter
France
|
KRAS silencing impacts chromatin organization and transcriptional activity in colorectal cancer cells
P-321
EACR25-0651
S
Poster Presenter
Portugal
|
Characterization of TRIB2 role in pancreatic cancer chemoresistance
P-322
EACR25-0659
In
Poster Presenter
Portugal
|
Identifying Therapeutic Vulnerabilities in KRASG12D-Resistant Pancreatic Cancer Using High-Throughput Drug Screening
P-323
EACR25-0711
Manzila Kuerbanjiang
Poster Presenter
Germany
|
Potential therapeutic implication of Epithelial Protein Lost in Neoplasm (EPLIN) in head and neck cancer and chemotherapy resistance
P-324
EACR25-0713
CAI WANG
Poster Presenter
United Kingdom
|
Combination therapy with YAP/TEAD and RAS inhibitors overcomes phenotypic cell plasticity-driven resistance in NRAS-mutated melanoma
P-325
EACR25-0739
Mira Kahil
Poster Presenter
France
|
The interplay between mechanisms of resistance and therapeutic targets: identifying novel treatments for drug-resistant BRAFV600E pediatric high-grade glioma
P-326
EACR25-0755
Rebecca Lehmann
Poster Presenter
Australia
|
Targeting ErbB receptor family to intercept therapy adaptation in ALK-positive lung cancer
P-327
EACR25-0781
JIAHAO TAO
Poster Presenter
Italy
|
The Role of NRG-1 in Resistance to Targeted Cancer Therapies in ERBB2-Amplified Breast Cancer
P-328
EACR25-0797
Mahtab Karbasian
Poster Presenter
Finland
|
Unraveling the Hidden Player: miR-188-5p at the Crossroads of DDR and PARP Inhibitor Resistance in Ovarian Cancer
P-329
EACR25-0897
Elif Merve Ayd
Poster Presenter
Turkey
|
Decoding drug resistance in cervical cancer cell lines: an AKT-independent mechanism
P-330
EACR25-0923
Nauf Bou Antoun
Poster Presenter
United Kingdom
|
Rituximab resistance shapes sensitivity to effector-cell mediated cytotoxicity in B-cell lymphoma
P-331
EACR25-0975
Aleksandra Maria Kusowska
Poster Presenter
Poland
|
Crosstalk between oncogenic signaling pathways as driver of therapy resistance against small molecule inhibitors in Glioblastoma
P-332
EACR25-0987
Mike van Heumen
Poster Presenter
Netherlands
|
Targeting Drug Resistance in Hepatocellular Carcinoma: Uncovering Metabolic Vulnerabilities for Therapeutic Re-Sensitization
P-333
EACR25-1015
Dzeneta Halilovic
Poster Presenter
Luxembourg
|
Investigating estrogen receptor fusion proteins as a mechanism of resistance to endocrine therapies in breast cancer
P-334
EACR25-1057
Anastasia Alataki
Poster Presenter
United Kingdom
|
Increased Sensitivity to BCL-2 Inhibition in EGFR-TKI Resistant NSCLC Cell Lines
P-335
EACR25-1105
Madeleine Jares
Poster Presenter
Germany
|
SPOCK1 is Linked to Mesenchymal-like Features and Drug Resistance in Melanoma Cells Treated with BRAF and MEK Inhibitors
P-336
EACR25-1107
Carme Sol
Poster Presenter
Spain
|
Combinatorial assessment of DXd-based antibody drug conjugates with DNA damage response inhibitors in ovarian and endometrial cancers
P-337
EACR25-1127
Yongda Li
Poster Presenter
Ireland
|
Unraveling Therapeutic Resistance in Patients with Early-Stage HER2-Negative Breast Cancer in the I-SPY2 Clinical Trial
P-338
EACR25-1205
Tam Binh Bui
Poster Presenter
United States
|
Pt1a and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma effect through RNA m6A methylation modification
P-339
EACR25-1273
Yinjia Huang
Poster Presenter
Hong Kong, China
|
SOAT1 Promotes Methotrexate Resistance in Choriocarcinoma
P-340
EACR25-1275
Mengxia Zheng
Poster Presenter
China
|
Creating Repotrectinib Resistance in a Ba/F3 SLC34A2-ROS1 NSCLC cell line
P-341
EACR25-1297
Patrick Korthuis
Poster Presenter
Netherlands
|
Targeting Fascin as a Therapeutic Approach to Overcome Oxaliplatin Resistance in Colorectal Cancer
P-342
EACR25-1307
Diogo Rafael Da Cruz Ribeiro
Poster Presenter
Spain
|
SRSF9-mediated alternative splicing impairs anti-tumor immunity and drives resistance to PD-L1/VEGF-A blockade in hepatocellular carcinoma
P-344
EACR25-1407
Jie Luo
Poster Presenter
Hong Kong, China
|
Revealing Distinct Oxaliplatin Resistance Mechanisms in HCT116 Cells Through Genomic and Transcriptomic Analysis Under Continuous and Intermittent Treatment Regimens
P-345
EACR25-1413
Gamze Yilmaz
Poster Presenter
Turkey
|
An unbiased in vitro screen for uncovering HER2 drug resistance mutations
P-346
EACR25-1461
Iman Farahani
Poster Presenter
Finland
|
Quantitative proteomics of drug-metabolizing enzymes and transporters in patients with appendix tumours
P-347
EACR25-1467
Areti-Maria Vasilogianni
Poster Presenter
United Kingdom
|
Establishment of chemoresistant patient-derived tumor organoids (PDTO) to identify relevant biomarkers for second-line treatments in ovarian cancer
P-348
EACR25-1477
Sahra Messaoudi
Poster Presenter
France
|
Lysosomal Ca2+ release via TRPML3 enhances drug sensitivity of gefitinib-resistance NSCLS cells
P-349
EACR25-1569
Sei-Hoon Yang
Poster Presenter
Korea (Republic of)
|
SOS1 inhibition enhances the efficacy of and delays resistance to oncogene-targeted therapies in lung adenocarcinoma
P-350
EACR25-1617
Robert L Kortum
Poster Presenter
United States
|
INTRINSIC MECHANISMS OF RESISTANCE TO CDK4/6 INHIBITORS IN LUMINAL METASTATIC BREAST CANCER
P-351
EACR25-1655
Maribel Aybar Molina
Poster Presenter
Spain
|
Overcoming Antibody-Drug Conjugate Resistance in HER2-Positive Breast Cancer: Insights into Molecular Mechanisms and Targeted Therapeutic Approaches
P-352
EACR25-1689
Queenie Yong
Poster Presenter
New Zealand
|
Chlorpromazine nanoparticles enhance anti-cancer effect of Doxorubicin nanoparticles preventing their extrusion
P-353
EACR25-1707
Abhisek Mishra
Poster Presenter
India
|
Involvement of Androgen Receptor/miR-181a-5p/c-Met Axis in the Progression of Prostate Cancer
P-354
EACR25-1709
Peyda Korhan
Poster Presenter
Turkey
|
miR-212-3p Down-Regulates the MAPK/ERK Pathway to Mitigate Oxaliplatin Resistance in Colorectal Cancer
P-355
EACR25-1715
Tsai-Yi Hsu
Poster Presenter
Taiwan
|
Functional and molecular changes implicated in doxorubicin resistance in breast cancer
P-356
EACR25-1777
Lenka Trnkova
Poster Presenter
Slovakia
|
Sensitization of ovarian cancers to ΡARΡ inhibitors by inductiοn of an ΗRD phenοtype: towards a medicine of precision based on UBE2Ν inhibitiοn.
P-357
EACR25-1781
L
Poster Presenter
France
|
A not expected effect of longterm temozolomide treatment on resistance of glioblastoma cells – an in vitro study
P-358
EACR25-1827
Claudia von Montfort
Poster Presenter
Germany
|
Intercellular Communication via Therapy-Induced Secretome Drives Chemoresistance in Ovarian Cancer Cells
P-359
EACR25-1885
Polina Shnaider
Poster Presenter
Russia
|
On-target mutations confer resistance to WRN helicase inhibitors in Microsatellite Unstable Cancer Cells.
P-360
EACR25-1893
GABRIELE PICCO
Poster Presenter
United Kingdom
|
The Role of AP-1 Target Transcript Vav3.1 in the Regulation of Osimertinib Resistance in Lung Adenocarcinoma
P-361
EACR25-1999
Nazife Ege G
Poster Presenter
Turkey
|
Unravelling PARP inhibitor resistance mechanisms in ovarian cancer
P-362
EACR25-2027
Adri
Poster Presenter
Spain
|
Identifying miR-7-5p/KEAP1/NRF2 and miR-122-5p/ADAM10/IL-6 signaling axes in Castration and Enzalutamide-resistant prostate cancer cells
P-363
EACR25-2033
Ceyda Nur Zaim
Poster Presenter
Turkey
|
Targeting ferroptosis resistance by inhibiting SCD1 in TNBC enhances tumor response to immunotherapy.
P-364
EACR25-2063
Quentin Herrera Garfia
Poster Presenter
Belgium
|
Tumor microenvironment determines immune resistance to chemoimmunotherapy in KRAS-mutant Non-Small Cell Lung Cancer: transcriptomic insights from a prospective cohort
P-904
EACR25-2083
Raquel Herrero
Poster Presenter
Spain
|
Targeting BCL-2 proteins as a Strategy Against Therapy Persistency in TNBC
P-365
EACR25-2121
T
Poster Presenter
Spain
|
Targeting Epigenetic Mechanisms to Overcome Drug Resistance in TaxaPlatin-Resistant Prostate Cancer
P-366
EACR25-2193
Neslihan Y
Poster Presenter
Turkey
|
CDK12/13 inhibition can counteract Epithelial Ovarian Cancer chemoresistance
P-367
EACR25-2239
Ilenia Pellarin
Poster Presenter
Italy
|
High resolution profiling of complex in vitro 3D lung cancer model to monitor resistance to immune checkpoint inhibitors
P-368
EACR25-2279
Hortense PERDRIEAU
Poster Presenter
France
|
EGFR/SHP2-targeted antibody-drug conjugate for colorectal cancer theranostics
P-369
EACR25-2319
Joana Filipa Santos
Poster Presenter
Portugal
|
Overcoming PARP inhibitor resistance in ovarian cancer: interest of the HDAC inhibitor belinostat
P-370
EACR25-2375
Sterenn Guillemot
Poster Presenter
France
|
Reducing Glioblastoma Treatment Heterogeneity Through Tumor Treating Fields Application Coupled With tmCLIC1 Impairment by Metformin
P-371
EACR25-2407
Michele Mazzanti
Poster Presenter
Italy
|
Cisplatin resistance hinders the response to CDK4/6 inhibitors in esophageal squamous cell carcinoma cells
P-373
EACR25-2503
Marta Avalos Moreno
Poster Presenter
Belgium
|
Targeting AURKA Overcomes Gemcitabine Resistance in TP53-Mutated Cancers by Disrupting the Replication Stress Response
P-374
EACR25-2593
Jian Wang
Poster Presenter
China
|